Comparison of capecitabine concentrations determined by microsampling versus plasma concentrations for therapeutic drug monitoring: a pilot study

- Shafiei, Mohsen, Galettis, Peter, Beale, Philip, Martin, Jennifer H., McLachlan, Andrew J., Blinman, Prunella

Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice

- Radovanovic, Mirjana, Galettis, Peter, Flynn, Alex, Martin, Jennifer H., Schneider, Jennifer J.

Therapeutic drug monitoring in anticancer agents: perspectives of Australian medical oncologists

- Flynn, Alexandra, Galettis, Peter, Gurney, Howard, Michael, Michael, Desar, Ingrid, Westerdijk, Kim, Schneider, Jennifer, Martin, Jennifer

Dried Blood Spot Sampling in the Monitoring of Anticancer Therapy for Solid Tumors: A Systematic Review

- Shafiei, Mohsen, Mahmood, Alina, Beale, Philip, Galettis, Peter, Martin, Jennifer, McLachlan, Andrew J., Blinman, Prunella

A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology

- Erku, Daniel, Schneider, Jennifer, Scuffham, Paul

Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology

- Menz, Bradley D., Stocker, Sophie L., Verougstraete, Nick, Kocic, Danijela, Galettis, Peter, Stove, Christophe P., Reuter, Stephanie E.

Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine

- Schneider, Jennifer J., Galettis, Peter, Martin, Jennifer H.

Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy

- Clarke, William A., Chatelut, Etienne, Fotoohi, Alan K., Larson, Richard A., Martin, Jennifer H., Mathijssen, Ron H. J., Salamone, Salvatore J.

Using Therapeutic Drug Monitoring and Pharmacovigilance to Overcome Some of the Challenges of Developing Medicinal Cannabis from Botanical Origins

- Dryburgh, Laura M., Martin, Jennifer H.

An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy

- Imani, Sahand, Buscher, Hergen, Day, Richard, Gentili, Sheridan, Jones, Graham R. D., Marriott, Debbie, Norris, Ross, Sandaradura, Indy

Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases

- Mitrev, N., Vande Casteele, N., Corte, C., Ghaly, S., Lemberg, D. A., Kariyawasam, V., Lewindon, P., Martin, J., Mountifield, R., Radford-Smith, G., Slobodian, P., Sparrow, M., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., Begun, J., Bryant, R., Chan, W.

Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours

- Goulooze, Sebastiaan C., Galettis, Peter, Boddy, Alan V., Martin, Jennifer H.

Clinical consequences of a miscalibrated digoxin immunoassay

- Lim, Aaron E., Tate, Jillian R., Clarke, David, Norris, Ross L., Morris, Raymond G., Martin, Jennifer H.

Implementation of a centralised aminoglycoside monitoring service

- O'Hara, Kate, Prior, Felicity H., Whyte, Ian M.